Why the study?
Does the Nobori drug-eluting stent demonstrate good clinical performance and safety in an unselected, real-world patient population undergoing percutaneous coronary intervention?
Population
3,067 consecutive patients undergoing a percutaneous coronary intervention in a real-world setting…
Design
Cohort
Follow-up
2 years
Authors
Loading...
Off-label Nobori use linked to higher TLF; leaves open whether biodegradable-polymer stents match on-label safety in unselected PCI.
Does the Nobori drug-eluting stent demonstrate good clinical performance and safety in an unselected, real-world patient population undergoing percutaneous coronary intervention?
The Nobori drug-eluting stent with a biodegradable polymer shows sustained safety and efficacy at two years in a real-world, unselected patient population, including high-risk patients with off-label indications.
Danzi et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: